

Salud y Vida, P.A.

Reporting Period : (1/1/2016 - 12/31/2016)

Payer Filter :	All Payers							
ID	Measure	NQS Domain	Num	Den	IPP	Excl	Ехср	Score
NQF 0002 (V4)	Appropriate Testing for Children with Pharyngitis	Efficient Use of Healthcare Resources	21	149	152	3	0	14%
NQF 0004 a (V4)	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Clinical Processes/Effec tiveness	0	1,335	1,959	624	0	0%
NQF 0004 a S1 (V4)	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment Patients age 13-17	Clinical Processes/Effec tiveness	0	8	15	7	0	0%
NQF 0004 a S2 (V4)	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment Patients age >=18	Clinical Processes/Effec tiveness	0	1,327	1,944	617	0	0%
NQF 0004 b (V4)	Initiation Engagement of Alcohol and Other Drugs	Clinical Processes/Effec tiveness	0	1,335	1,959	624	0	0%
NQF 0004 b S1 (V4)	Initiation Engagement of Alcohol and Other Drugs Patients age 13-17	Clinical Processes/Effec tiveness	0	8	15	7	0	0%
NQF 0004 b S2 (V4)	Initiation Engagement of Alcohol and Other Drugs Patients age >=18	Clinical Processes/Effec tiveness	0	1,327	1,944	617	0	0%
NQF 0018 (V4)	Controlling High Blood Pressure	Clinical Processes/Effec tiveness	2,267	3,122	3,190	68	0	73%
NQF 0022 a (V4)	Use Of High Risk Meds In Elderly	Patient Safety	573	2,754	2,754	0	0	21%
NQF 0022 b (V4)	Use High Risk Elderly Med Greater than 2 Counts	Patient Safety	104	2,754	2,754	0	0	4%
NQF 0024 a (V4)	BMI Child 3 to 17 Performed	Population and Public Health	1,196	1,207	1,252	45	0	99%
NQF 0024 a S1 (V4)	BMI Child 3 to 17 Performed Patients age 3-10	Population and Public Health	514	524	559	35	0	98%
NQF 0024 a S2 (V4)	BMI Child 3 to 17 Performed Patients age 11-16	Population and Public Health	682	683	693	10	0	100%
NQF 0024 b (V4)	Nutrition Counseling Child 3 to 17 Performed	Population and Public Health	23	1,207	1,252	45	0	2%
NQF 0024 b S1 (V4)	Nutrition Counseling Child 3 to 17 Performed Patients age 3-10	Population and Public Health	8	524	559	35	0	2%
NQF 0024 b S2 (V4)	Nutrition Counseling Child 3 to 17 Performed Patients age 11-16	Population and Public Health	15	683	693	10	0	2%
NQF 0024 c (V4)	Activity Counseling Child 3 to 17 Performed	Population and Public Health	25	1,207	1,252	45	0	2%
NQF 0024 c S1 (V4)	Activity Counseling Child 3 to 17 Performed Patients age 3-10	Population and Public Health	6	524	559	35	0	1%
NQF 0024 c S2 (V4)	Activity Counseling Child 3 to 17 Performed Patients age 11-16	Population and Public Health	19	683	693	10	0	3%
NQF 0028 (V4)	Preventive Care and Screening Tobacco Use Screening and Cessation Intervention	Population and Public Health	8,350	8,778	8,778	0	0	95%
NQF 0032 (V4)	Cervical Cancer Screening	Clinical Processes/Effec tiveness	1,645	3,104	3,727	623	0	53%
NQF 0033 (V4)	Chlamydia Screening for Women	Population and Public Health	26	219	226	7	0	12%
NQF 0033 S1 (V4)	Chlamydia Screening for Women Patients age 16-19	Population and Public Health	19	112	117	5	0	17%
NQF 0033 S2 (V4)	Chlamydia Screening for Women Patients age 20-23	Population and Public Health	7	107	109	2	0	7%
NQF 0034 (V4)	Colorectal Cancer Screening	Clinical Processes/Effec tiveness	3,679	4,773	4,811	38	0	77%
NQF 0036 (V4)	Use of Appropriate Medications for Asthma	Clinical Processes/Effec tiveness	24	34	54	20	0	71%
NQF 0036 S1 (V4)	Use of Appropriate Medications for Asthma Patients age 5-10	Clinical Processes/Effec tiveness	7	10	17	7	0	70%
NQF 0036 S2 (V4)	Use of Appropriate Medications for Asthma Patients age 11-17	Clinical Processes/Effec tiveness	5	8	10	2	0	63%



Measure **NQS Domain** Num Den IPP Excl Ехср Score Clinical NQF 0036 S3 (V4) Processes/Effec 3 0 64% Use of Appropriate Medications for Asthma Patients age 18-49 14 11 tiveness Clinical NQF 0036 S4 (V4) Use of Appropriate Medications for Asthma Patients age 50-63 Processes/Effec 5 5 13 8 0 100% tiveness Population and NQF 0038 (V4) Childhood Immunization Status 19 60 60 0 0 32% Public Health Population and Preventive Care and Screening Influenza Immunization 458 11.639 0 6% NQF 0041 (V5) 8.148 11 Public Health Clinical Processes/Effec 46% NQF 0043 (V4) Pneumonia Vaccination Status for Older Adults 2.967 2.967 0 0 1.361 tiveness Efficient Use of NQF 0052 (V5) Use of Imaging Studies for Low Back Pain Healthcare 302 316 897 581 0 96% Resources Clinical NQF 0055 (V4) Diabetes Eye Exam Processes/Effec 6 2,601 2,601 0 0 0% tiveness Clinical NQF 0056 (V4) Diabetes Foot Exam Processes/Effec 41 2,582 2.601 19 0 2% tiveness Clinical NQF 0059 (V4) Diabetes Hemoglobin A1c Poor Control Processes/Effec 405 2.601 2.601 0 0 16% Clinical NQF 0060 (V4) 5 8 0 0 63% Hemoglobin A1c Test for Pediatric Patients 8 Processes/Effec tiveness NQF 0062 (V4) Diabetes Urine Protein Screening Processes/Effec 2,491 2,601 2,601 0 0 96% tiveness Clinical Processes/Effec 0 NQF 0068 (V4) IVD Use of Aspirin or Another Antithrombotic 875 1,172 1,172 0 75% tiveness Efficient Use of NQF 0069 (V4) Approp Treatment for Children with Upper Resp Infection Healthcare 43 45 215 170 O 96% Resources Clinical CAD Beta Blocker Therapy for Moderate to Severe LVSD or LVEF less NQF 0070 a (V4) Processes/Effec 0 683 0 0 0% than 40 percent Clinical 0% NQF 0070 b (V4) 0 0 683 0 0 CAD Beta Blocker Therapy for Prior Myocardial Infarction Processes/Effec tiveness Clinical NQF 0081 (V4) Heart Failure ACE Inhibitor or ARB Therapy for LVSD Processes/Effec 0 0 400 0 0 0% tiveness Clinical NQF 0083 (V4) Heart Failure Beta Blocker Therapy for LVSD 0 0 0 Processes/Effec 0 400 0% tiveness NQF 0101 (V4) Falls Screening for Future Fall Risk Patient Safety 784 2,885 2,967 0 82 27% Clinical O NOF 0104 (V4) Adult Major Depressive Disorder Suicide Risk Assessments Processes/Effec 0 8 9 1 6 8 9 1 6 0 0% tiveness Clinical NQF 0105 a (V4) Antidepressant Medication for at Least 84 days Processes/Effec 13 78 329 251 0 17% tiveness Clinical 0 NQF 0105 b (V4) Antidepressant Medication for at Least 180 days Processes/Effec 2 78 329 251 3% tiveness Clinical ADHD Follow Up Care for Children Prescribed ADHD Meds During 30 Day NQF 0108 a (V5) Processes/Effec 6 26 44 18 0 23% Initiation Phase tiveness Clinical ADHD Follow Up Care for Children Prescribed ADHD Meds Visit with 2 NQF 0108 b (V5) Processes/Effec 0 1 0 0 0% Plus Followups tiveness Patient and NQF 0384 (V4) Oncologys Medical and Radiation Pain Intensity Quantified Family 0 0 0 0 0 0% Engagement Clinical NQF 0385 (V5) Colon Cancer Chemotherapy for AJCC Stage III Colon Cancer Patients Processes/Effec 0 0 32 0 0 0% tiveness Clinical Breast Cancer Hormonal Therapy for Stage IC IIIC Estrogen or Progeteron O 95 O 0% NQF 0387 (V4) Processes/Effec 0 O Receptor tiveness Efficient Use of Prostate Cancer Avoidance of Overuse of Bone Scan for Staging Low Risk NQF 0389 (V5) Healthcare 0 0 121 0 0 0% **Prostate Cancer Patients** Resources Clinical NQF 0405 a (V4) HIV AIDS PCP prophylaxis within 3 months of CD4 below 200 0 0 0 0% Processes/Effec tiveness



Measure **NQS Domain** Num Den IPP Excl Excp Score Clinical HIV AIDS PCP prophylaxis within 3 months of CD4 below 500 or 15 NQF 0405 b (V4) Processes/Effec 0 0 0 0 0 0% percent tiveness Clinical NQF 0405 c (V4) HIV AIDS PCP prophylaxis at time of HIV diagnosis Processes/Effec 0 0 0 0 0 0% tiveness Population and NQF 0418 (V5) Preventive Care and Screening for Clinical Depression and Follow Up Plan 0 7,908 10,975 3,067 0 0% Public Health 0 NQF 0419 (V5) Documentation of Current Meds in the Medical Record Patient Safety 26.967 29.978 29.978 0 90% Population and NQF 0421 a (V4) BMI Adult 18 to 64 Performed 0 47% 3,295 6,994 7,236 242 Public Health Population and NQF 0421 b (V4) BMI Adult 65 or Older Performed 1,702 2,941 2,971 30 0 58% Public Health Clinical NQF 0710 (V4) Processes/Effec 0 0 0 0 Depression Remission at Twelve Months 0 0% tiveness Clinical 0 NQF 0712 a (V4) Depression Utilization of the PHQ 9 Tool Last 4 months Processes/Effec 0 1,794 1,955 161 0% tiveness NQF 0712 b (V4) Depression Utilization of the PHQ 9 Tool Second 4 Months Processes/Effec 0 2.090 2,263 173 0 0% tiveness Clinical NQF 0712 c (V4) Depression Utilization of the PHQ 9 Tool First 4 Months Processes/Effec 2.122 2,300 178 0 0% tiveness Child and Adolescent Major Depressive Disorder Suicide Risk NQF 1365 (V4) Patient Safety 0 77 77 0 0 0% Assessments Clinical CMS 125 (V4) **Breast Cancer Screening** Processes/Effec 2.181 2,964 2,966 2 0 74% tiveness Clinical 2 0% CMS 149 (V4) Dementia Cognitive Assessment 0 176 178 O Processes/Effec tiveness Clinical 0 0 0% CMS 158 (V4) Pregnant women that had HBsAg testing Processes/Effec 0 0 0 tiveness Clinical 0 49% CMS 163 (V4) Processes/Effec 1.285 2.601 2.601 0 Diabetes Low Density Lipoprotein Management tiveness Bipolar Disorder and Major Depression Appraisal for alcohol or chemical 1,174 1,174 CMS 169 (V4) Processes/Effec 0 O O 0% substance use tiveness Clinical CMS 182 a (V5) IVD Complete Lipid Panel and LDL Control Processes/Effec 1.172 1.172 0 0 78% tiveness Clinical 58% CMS 182 b (V5) IVD Complete Lipid Panel and LDL Control less than 100 677 1 172 1 172 0 0 Processes/Effec tiveness Preventive Care and Screening for High Blood Pressure and Follow Up Population and CMS 22 (V4) 4,529 9,713 10,227 450 64 47% Public Health Care 1,073 6,680 6,680 0 0 16% CMS 50 (V4) Closing the referral loop receipt of specialist report Coordination Patient and CMS 56 (V4) Functional Status Assessment for Hip Replacement O O O 0 0 0% Family Engagement Clinical CMS 62 (V4) HIV AIDS Medical Visit Processes/Effec 16 32 32 0 0 50% tiveness Clinical CMS 65 (V5) Hypertension Improvement in Blood Pressure Processes/Effec 37 210 212 2 0 18% tiveness Patient and 0 0 0% CMS 66 (V4) Functional Status Assessment for Knee Replacement Family 0 0 0 Engagement Clinical Primary Caries Prevention Intervention as Offered by Primary Care CMS 74 (V5) Processes/Effec 2 1,825 1,825 0 0 0% Providers including Dentists tiveness Clinical Primary Caries Prevention Intervention as Offered by Primary Care CMS 74 S1 (V5) 2 276 276 0 0 1% Processes/Effect Providers including Dentists Patients age 0-4 tiveness Clinical Primary Caries Prevention Intervention as Offered by Primary Care CMS 74 S2 (V5) Processes/Effec 0 538 538 0 0 0% Providers including Dentists Patients age 5-11 tiveness Clinical Primary Caries Prevention Intervention as Offered by Primary Care CMS 74 S3 (V5) Processes/Effec 0 1,011 1,011 0 0 0% Providers including Dentists Patients age 12-19 tiveness Clinical O O CMS 75 (V4) Children Who Have Dental Decay or Cavities Processes/Effect 24 1.825 1 825 1% tiveness



Measure NQS Domain Num Den Excl Excp Score Clinical Processes/Effec 16 16 0 CMS 77 (V4) HIV AIDS RNA Control for Patients with HIV 0 0% tiveness Population and 0 16 16 CMS 82 (V3) Maternal Depression Screening 0 0 Public Health Patient and CMS 90 (V5) 0% Functional Status Assessment for Complex Chronic Conditions 5 0 Farnily Engagement